Highlights newsletter 3
This newsletter presents you the following key sessions:
1. Video-interview with Dr. Marc André on the final analysis of the DASISION study with 5 years of follow-up
2. Carfilzomib represents a potent and effective addition to standard multiple myeloma therapy
3. Faster and deeper reductions in BCR-ABL levels with ponatinib translate into better long-term outcomes
for patients with refractory CML
4. Stem cell transplantation is a safe treatment option for patients with HIV-related lymphoma
5. Children with T-lymphocytic leukemia have better outcomes than expected, regardless of the presence
of an early thymic precursor protein signature